The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates - PubMed (original) (raw)

The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates

A HORITA et al. Biochem Pharmacol. 1961 Jul.

No abstract available

PubMed Disclaimer

Similar articles

• Dephosphorylation of psilocybin to psilocin by alkaline phosphatase.
  HORITA A, WEBER LJ. HORITA A, et al. Proc Soc Exp Biol Med. 1961 Jan;106:32-4. doi: 10.3181/00379727-106-26228. Proc Soc Exp Biol Med. 1961. PMID: 13715851 No abstract available.
• [Serotonin metabolism in experimental psilocybin psychosis].
  VITEK V, VOJTECHOVSKY M, GROF S. VITEK V, et al. Act Nerv Super (Praha). 1961 May;3:213-5. Act Nerv Super (Praha). 1961. PMID: 13926289 Czech. No abstract available.
• Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.
  Dinis-Oliveira RJ. Dinis-Oliveira RJ. Drug Metab Rev. 2017 Feb;49(1):84-91. doi: 10.1080/03602532.2016.1278228. Epub 2017 Jan 31. Drug Metab Rev. 2017. PMID: 28074670 Review.
• alpha-Oxidation of indoleacetonitrile.
  TAYLOR HF, WAIN RL. TAYLOR HF, et al. Nature. 1959 Oct 10;184(Suppl 15):1142. doi: 10.1038/1841142a0. Nature. 1959. PMID: 13837151 No abstract available.
• [Psilocybin - public available psychodysleptic].
  Dydak K, Śliwińska-Mossoń M, Milnerowicz H. Dydak K, et al. Postepy Hig Med Dosw (Online). 2015 Sep 7;69:986-95. Postepy Hig Med Dosw (Online). 2015. PMID: 26400885 Review. Polish.

Cited by

• Psilocybin for the treatment of Alzheimer's disease.
  Zheng S, Ma R, Yang Y, Li G. Zheng S, et al. Front Neurosci. 2024 Jul 10;18:1420601. doi: 10.3389/fnins.2024.1420601. eCollection 2024. Front Neurosci. 2024. PMID: 39050672 Free PMC article. Review.
• Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships.
  Kovacic P, Somanathan R. Kovacic P, et al. Oxid Med Cell Longev. 2009 Sep-Oct;2(4):181-90. doi: 10.4161/oxim.2.4.9380. Oxid Med Cell Longev. 2009. PMID: 20716904 Free PMC article.
• In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin.
  Jones NT, Wagner L, Hahn MCP, Scarlett CO, Wenthur CJ. Jones NT, et al. Front Psychiatry. 2024 Jan 8;14:1303365. doi: 10.3389/fpsyt.2023.1303365. eCollection 2023. Front Psychiatry. 2024. PMID: 38264637 Free PMC article.
• Injury-Triggered Blueing Reactions of Psilocybe "Magic" Mushrooms.
  Lenz C, Wick J, Braga D, García-Altares M, Lackner G, Hertweck C, Gressler M, Hoffmeister D. Lenz C, et al. Angew Chem Int Ed Engl. 2020 Jan 20;59(4):1450-1454. doi: 10.1002/anie.201910175. Epub 2019 Dec 4. Angew Chem Int Ed Engl. 2020. PMID: 31725937 Free PMC article.
• Development of a psilocin immunoassay for serum and blood samples.
  Albers C, Köhler H, Lehr M, Brinkmann B, Beike J. Albers C, et al. Int J Legal Med. 2004 Dec;118(6):326-31. doi: 10.1007/s00414-004-0469-9. Epub 2004 Aug 3. Int J Legal Med. 2004. PMID: 15526212

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database